Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
192 hedge funds and large institutions have $446M invested in Sage Therapeutics in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 43 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
79% more call options, than puts
Call options by funds: $7.52M | Put options by funds: $4.19M
7% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 55
4% less funds holding
Funds holding: 199 → 192 (-7)
6.16% less ownership
Funds ownership: 84.18% → 78.02% (-6.2%)
12% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 43
19% less capital inflows, than outflows
Capital inflows: $114M | Capital outflows: $141M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Madison Avenue Partners
New York
|
+$11.8M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.3M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$10.1M |
| 4 |
Alpine Associates Management
Palm Beach,
Florida
|
+$9.37M |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$7.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Caligan Partners
New York
|
-$24.3M |
| 2 |
TIG Advisors LLC
New York
|
-$19.5M |
| 3 |
Deep Track Capital
Greenwich,
Connecticut
|
-$16.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.3M |
| 5 |
Boothbay Fund Management
New York
|
-$11M |
SAGE Hedge Fund Activity: Q2 2025 in Review
192 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2025, worth a combined $446M — up 8.3% from $411M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of SAGE and 38 opened new positions — a net loss of 5 holders — while 55 trimmed existing stakes and 59 added.
The largest buyer was Madison Avenue Partners, adding an estimated $11.8M. The largest seller was Caligan Partners, exiting entirely with an estimated $24.3M sold.
- 192 institutional investors held Sage Therapeutics (SAGE) as of Q2 2025, down from 199 in Q1 2025.
- Funds reported $446M of Sage Therapeutics stock for Q2 2025, up 8.3% quarter-over-quarter.
- 38 funds opened new Sage Therapeutics positions in Q2 2025 and 43 closed out, a net change of -5 holders.
- The largest Sage Therapeutics buyer in Q2 2025 was Madison Avenue Partners, an estimated $11.8M added.
- The largest Sage Therapeutics seller in Q2 2025 was Caligan Partners, an estimated $24.3M sold.
Based on aggregated 13F filings for Q2 2025.